The Seven Trial: Exploiting the Unfolded Protein Response
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The goal of this investigator initiated interventional study is to improve the response to
the anticancer treatments (chemotherapy) in people who have previously untreated metastatic
pancreas cancer. The main question it aims to answer is:
• Do new types of immune-based therapies, called botensilimab, and balstilimab, when given in
combination with chemotherapy consisting of nab-paclitaxel + gemcitabine + cisplatin, and
oral medications of chloroquine and celecoxib help patients with previously untreated
metastatic pancreatic cancer?
Participants will be administered two immune-based therapies:
- Botensilimab (also referred to as AGEN1811)
- Balstilimab (also referred to as AGEN2034)
Patients will be evaluated when given in combination with:
- Triple chemotherapy (nab-paclitaxel + gemcitabine + cisplatin), plus two oral
medications:
- chloroquine
- celecoxib
Phase:
Phase 1
Details
Lead Sponsor:
HonorHealth Research Institute
Collaborators:
Agenus Inc. Translational Genomics Research Institute University of Arizona